misspelledsearch.com:glucosamine jointinformation page
If you cannot find the information you are searching for on this page, we suggest searching Google with the correct spelling "glucosamine joint":
Chemical structure of α-D-glucosamine Glucosamine (C6H14NO5) is an amino sugar that is a important precursor in the biochemical synthesis of glycosylated proteins and lipids. Glucosamine is commonly used as a treatment for osteoarthritis, although its acceptance as a medical therapy varies.
BiochemistryD-Glucosamine is made naturally in the form of glucosamine-6-phosphate, and is the biochemical precursor of all nitrogen-containing sugars (Roseman et al., 2001). Specifically, glucosamine-6-phosphate is synthesized from fructose-6-phosphate and glutamine (Ghosh et al., 1960) as the first step of the hexosamine biosynthesis pathway [1]. The end-product of this pathway is UDP-N-acetylglucosamine, which is then used for making glycosaminoglycans, proteoglycans, and glycolipids. As the formation of glucosamine-6-phosphate is the first step for the synthesis of these products, glucosamine may be important in regulating their production. However, the way that the hexosamine biosynthesis pathway is actually regulated, and whether this could be involved in contributing to human disease, remains unclear (Buse, 2006). Health EffectsTreatment with oral glucosamine is commonly used for the treatment of osteoarthritis. Since glucosamine is a precursor for glycosaminoglycans, and glycosaminoglycans are a major component of joint cartilage, supplemental glucosamine may help to rebuild cartilage and treat arthritis. However, there is little evidence that any clinical effect of glucosamine works this way (Laverty et al., 2005; Biggee et al., 2005). Its use as a therapy for osteoarthritis appears safe but there is conflicting evidence as to its effectiveness. UsageA typical dosage of glucosamine salt is 1,500 mg per day. Glucosamine contains an amino group that is positively charged at physiological pH. The anion included in the salt may vary. Commonly sold forms of glucosamine are glucosamine sulfate and glucosamine hydrochloride. The amount of glucosamine present in 1500 mg of glucosamine salt will depend on which anion is present [2] and whether additional salts are included in the manufacturer's calculation. Glucosamine is often sold in combination with other supplements such as chondroitin sulfate and methylsulfonylmethane. In the United States, glucosamine is not approved by the Food and Drug Administration for medical use in humans. However, since glucosamine is classified as a dietary supplement, evidence of safety and efficacy is not required, so long as not advertised as treatment for a medical condition [3]. Nevertheless, glucosamine is a popular alternative medicine and has become extensively used by consumers for the treatment of osteoarthritis. It is also considered an acceptable treatment in veterinary medicine. In Europe, glucosamine is approved as a medical drug and is sold by Rottapharm (in the form of glucosamine sulfate). SafetyGlucosamine has been studied as a medical therapy since at least the early 1980s. The clinical studies have consistently reported that glucosamine appears safe. One caveat is that individuals with an allergy to shellfish may need to avoid glucosamine, as it is is usually derived from shellfish. There are vegetarian sources available. Another concern has been that the extra glucosamine could contribute to diabetes by interfering with the normal regulation of the hexosamine biosynthesis pathway (Buse, 2006), but several investigations have found no evidence that this occurs (Scroggie et al., 2003). Finally, in the United States, glucosamine is sold as a dietary supplement with no standards or certifications, and there is some evidence that the actual content of glucosamine may differ substantially from the labelled content [4]. Clinical StudiesThere have been multiple clinical trials of glucosamine as a medical therapy for osteoarthritis, but results have been conflicting. The evidence both for and against glucosamine's efficacy has led to ongoing debate among physicians about whether to recommend glucosamine treatment to their patients (Manson and Rahman, 2004). Multiple clinical trials in the 1980s and 1990s, all sponsored by the European patent-holder (Rottapharm), demonstrated a benefit for glucosamine. However, these studies were of poor quality due to short-comings in their methods, including small size, short duration, poor analysis of drop-outs, and unclear procedures for blinding (Adams, 1999; McAlindon et al., 2000). Rotta then sponsored two large (at least 100 patients per group), three-year-long, placebo-controlled clinical trials of the Rottapharm brand of glucosamine sulfate. These studies both demonstrated a clear benefit for glucosamine treatment (Reginster et al., 2001; Pavelká et al., 2002). There was not only an improvement in symptoms but also an improvement in joint space narrowing on radiographs. This suggested that glucosamine, unlike pain relievers such as NSAIDs, can actually help prevent the destruction of cartilage that is the hallmark of osteoarthritis. On the other hand, several subsequent studies, independent of Rottapharm, but smaller and shorter, did not detect any benefit of glucosamine (Hughes et al., 2002; Cibere et al., 2004).
Although the study found no effect for the supplements overall, a secondary analysis of a subgroup of patients suggested that the supplements might help people with pain classified as moderate to severe (see testing hypotheses suggested by the data). In an accompanying editorial, Dr. Marc Hochberg also noted that "It is disappointing that the GAIT investigators did not use glucosamine sulfate ... since the results would then have provided important information that might have explained in part the heterogeneity in the studies reviewed by Towheed and colleagues" (Hochberg et al., 2006). But this concern is not shared by pharmacologists at the PDR who state, "The counter anion of the glucosamine salt (i.e. chloride or sulfate) is unlikely to play any role in the action or pharmacokinetics of glucosamine"[6]. Thus the question of glucosamine's efficacy will not be resolved without further updates or trials. References
External links
This glucosamine joint index site has been developed to help wayward users find the information they are looking for, no matter how they are mistakenly spelled or mistyped. This site is designed to help users find glucosamine joint information for the following query variants:
If you would like to add or correct the content of this site, or if you are interested in supporting the efforts of misspelledsearch.com by placing your product information on these glucosamine joint pages, please contact mistype@gmail.com for details. This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "glucosamine". |